Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Primary Objective of Part 1 (Dose Escalation Phase): Evaluate the safety and tolerability of
SKL27969, and determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose
(RP2D) of SKL27969
Primary Objective of Part 2 (Dose Expansion Phase): Evaluate the preliminary anti-tumor
activity of SKL27969